Cargando…

Repurposing existing drugs for new uses: a cohort study of the frequency of FDA-granted new indication exclusivities since 1997

BACKGROUND: Drug repurposing (i.e., finding novel uses for existing drugs) is essential for maximizing medicines’ therapeutic utility, but obtaining regulatory approval for new indications is costly. Policymakers have therefore created temporary indication-specific market exclusivities to incentiviz...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sahragardjoonegani, Babak, Beall, Reed F., Kesselheim, Aaron S., Hollis, Aidan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7780607/ https://www.ncbi.nlm.nih.gov/pubmed/33397471 http://dx.doi.org/10.1186/s40545-020-00282-8

Ejemplares similares

Patents and regulatory exclusivities on FDA-approved insulin products: A longitudinal database study, 1986–2019
por: Olsen, Anders, et al.
Publicado: (2023)

Premarket Development Times for Innovative Vaccines––To What Extent Are the Coronavirus Disease 2019 (COVID-19) Vaccines Outliers?
por: Beall, Reed F, et al.
Publicado: (2021)

The Vexing Voyage of Vasopressin: The Consequences of Granting Market Exclusivity to Unapproved Drugs
por: Bendicksen, Liam, et al.
Publicado: (2022)

Repurposing of existing FDA approved drugs for Neprilysin inhibition: An in-silico study
por: Sankhe, Runali, et al.
Publicado: (2021)

Global clinical trial mobilization for COVID-19: higher, faster, stronger
por: Beall, Reed F., et al.
Publicado: (2020)

New Government Grants
Publicado: (1914)

Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis
por: Beall, Reed, et al.
Publicado: (2012)

The private versus public contribution to the biomedical literature during the COVID-19, Ebola, H1N1, and Zika public health emergencies
por: Beall, Reed F., et al.
Publicado: (2021)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

Evidence at time of regulatory approval and cost of new antibiotics in 2016-19: cohort study of FDA approved drugs
por: Mitra-Majumdar, Mayookha, et al.
Publicado: (2022)

Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs
por: Kouznetsova, Valentina L., et al.
Publicado: (2020)

Japanese government research grants for Kampo medicine: an overview of 10 years (1997–2017)
por: Hyun, Min Kyung, et al.
Publicado: (2019)

Repurposing of FDA-approved drugs against cancer – focus on metastasis
por: Ozsvári, Béla, et al.
Publicado: (2016)

Repurposing ferumoxytol: Diagnostic and therapeutic applications of an FDA-approved nanoparticle
por: Huang, Yue, et al.
Publicado: (2022)

Overview: Medicare Post-Acute Care Since the Balanced Budget Act of 1997
por: Cotterill, Philip G., et al.
Publicado: (2002)

Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?
por: Zaidi, Asifa, et al.
Publicado: (2015)

Repurposing FDA approved drugs as radiosensitizers for treating hypoxic prostate cancer
por: Bibby, Becky A. S., et al.
Publicado: (2021)

REPURPOSING OF FDA APPROVED COMPOUNDS TO INHIBIT OSM/OSMR SIGNALING IN GLIOBLASTOMA
por: Lotfipour, Farzaneh, et al.
Publicado: (2023)

Persistence of resistance: a panel data analysis of the effect of antibiotic usage on the prevalence of resistance
por: Rahman, Sakib, et al.
Publicado: (2023)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
por: Miller, Kathleen L., et al.
Publicado: (2020)

New Protocol grants CERN privileges and immunities
Publicado: (2007)

The next forum for unraveling FDA off-label marketing rules: State and federal legislatures
por: Sinha, Michael S., et al.
Publicado: (2018)

Anti-COVID drugs: repurposing existing drugs or search for new complex entities, strategies and perspectives
por: Pawełczyk, Anna, et al.
Publicado: (2020)

Organic materials repurposing, a data set for theoretical predictions of new applications for existing compounds
por: Omar, Ömer H., et al.
Publicado: (2022)

Mental Research and Government Grants: How Best to Assist Existing Laboratories
por: Bolton, Joseph Shaw
Publicado: (1913)

Dioxin Revisited: Developments Since the 1997 IARC Classification of Dioxin as a Human Carcinogen
por: Steenland, Kyle, et al.
Publicado: (2004)

Fire carbon emissions over maritime southeast Asia in 2015 largest since 1997
por: Huijnen, V., et al.
Publicado: (2016)

Collaborative Use Repurposing Engine (CURE): FDA-NCATS/NIH Effort to Capture the Global Clinical Experience of Drug Repurposing to Facilitate Development of New Treatments for Neglected and Emerging Infectious Diseases
por: Stone, Heather, et al.
Publicado: (2017)

Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans
por: Kim, Kevin, et al.
Publicado: (2015)

Repurposing FDA-approved sulphonamide carbonic anhydrase inhibitors for treatment of Neisseria gonorrhoeae
por: Abutaleb, Nader S., et al.
Publicado: (2021)

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML
por: James, Jenna R., et al.
Publicado: (2023)

Impact of Nutrition or FDA-Approved Medicine Repurposing on Metabolic Syndrome and Diabetic Complications
por: Cai, Lu
Publicado: (2023)

Participation of Black US Residents in Clinical Trials of 24 Cardiovascular Drugs Granted FDA Approval, 2006-2020
por: Chen, Siliang, et al.
Publicado: (2021)

Timing of Confirmatory Trials for Drugs Granted Accelerated Approval Based on Surrogate Measures From 2012 to 2021
por: Deshmukh, Anjali D., et al.
Publicado: (2023)

Big data and data repurposing - using existing data to answer new questions in vascular dementia research
por: Doubal, Fergus N., et al.
Publicado: (2017)

Repurposing Existing Drugs for the Treatment of COVID-19
por: Farne, Hugo, et al.
Publicado: (2020)

BES announce new COVID-19 research grant
Publicado: (2020)

Repurposing FDA-approved drugs as therapeutics to treat Rift Valley fever virus infection
por: Benedict, Ashwini, et al.
Publicado: (2015)

Can an FDA-Approved Alzheimer’s Drug Be Repurposed for Alleviating Neuronal Symptoms of Zika Virus?
por: Sirohi, Devika, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_0ckoedp5jq03epdvmdv7o05qlv